Are Allergy Shots Real Immunotherapy? Yes — Here Is the Evidence

Yes — allergy shots are definitively a form of immunotherapy. The medical term is subcutaneous immunotherapy (SCIT), and it is the oldest and most extensively studied allergen immunotherapy modality, with a published clinical record dating to 1911. The WHO classified allergen immunotherapy as the only disease-modifying allergy treatment in its 1998 Position Paper. While popular media has increasingly used 'immunotherapy' to describe cancer treatments, the term is older in allergy medicine by approximately 100 years, and the two treatments work through fundamentally different mechanisms — allergy AIT induces immune tolerance, while cancer immunotherapy activates immune attack.

Completing a 3 to 5-year course of allergy shots produces sustained benefit that can last 3 to 12 years after stopping, depending on treatment duration, allergen type, and individual patient factors. Durham et al. (NEJM 1999) demonstrated in a rigorous randomized discontinuation trial that patients who stopped grass SCIT after 3-4 years had symptom scores indistinguishable from patients who continued, for at least 3 follow-up years. Eng et al. (Allergy 2006) documented that childhood grass SCIT produced significant symptom and medication reduction persisting 12 years after stopping. Shorter courses produce shorter or no post-treatment benefit — the GRASS trial confirmed 2-year courses provide no lasting post-treatment remission. The minimum recommended duration is 3 years.

Evidence supports a protective effect against asthma development in children with allergic rhinitis receiving allergy shots, though the data come primarily from one major trial. The PAT study (Möller et al., JACI 2002, n=205 children with grass and birch pollen rhinoconjunctivitis) found significantly reduced asthma development during the 3-year SCIT course. Jacobsen's 10-year follow-up (Allergy 2007) found asthma in only 25% of SCIT-treated children versus 45% of controls — 7 years after treatment had ended — corresponding to an odds ratio of 2.5 in favor of SCIT. A separate pediatric retrospective across over 118,000 patients (Schmitt et al., JACI 2015) also showed reduced asthma incidence with AIT. Most guideline bodies now recognize asthma prevention in pollen-allergic children as an established benefit of appropriately selected allergy immunotherapy.

Observational evidence suggests allergy shots in monosensitized patients can reduce the development of new allergic sensitizations, though randomized trial data are limited. Purello-D'Ambrosio et al. (Clin Exp Allergy 2001, retrospective n=7,182 patients) found polysensitization developed in only 23.75% of monosensitized patients who received SCIT versus 68.03% of untreated patients over 4 years. Eng et al. (Allergy 2006) documented at 12-year follow-up that only 61% of formerly monosensitized SCIT patients developed new perennial sensitizations versus 100% of controls. However, Di Bona's systematic review (Allergy 2017) concluded that randomized trial evidence for this outcome is inconclusive, with most positive findings coming from non-randomized cohorts vulnerable to selection bias.

Despite sharing the word 'immunotherapy,' allergy shots and cancer treatment work through entirely opposite immune mechanisms and were developed independently. Allergy shots (SCIT) induce immune tolerance — they train regulatory T cells and IgG4 antibodies to suppress the overactive IgE response that causes allergic symptoms. Cancer immunotherapy (checkpoint inhibitors, CAR-T) removes inhibitory signals from the immune system to enhance its ability to recognize and destroy tumor cells. Allison's 2011 Nobel Prize-winning work on CTLA-4 led to ipilimumab; Noon and Freeman's 1911 work on subcutaneous allergen injection led to allergy shots. The two treatments are not related mechanistically, are used for entirely different conditions, and produce opposite types of immune modulation — one suppressing, one activating.

Clinical trial completion rates show 80-90% of patients who complete a full 3-5 year course of allergy shots report significant symptom improvement (Eng 2006). Real-world observational cohorts support this — Lee et al. (Allergy Asthma Immunol Res 2018, n=304 HDM SCIT) found 76.6% cumulative clinical remission in patients completing treatment. Average effect sizes across trials — roughly a 33% reduction in symptom scores — understate the response in well-matched patients with adequate allergen dosing. The qualifier 'well-matched' is important: the 20-50% low-responder rate in practice is driven primarily by inadequate allergen selection, subtherapeutic dosing, insufficient treatment duration, and early discontinuation — not failure of the immunologic mechanism itself. Patients who complete 3+ years with correctly identified allergens at effective maintenance doses achieve substantially better outcomes than population averages suggest.